ALSO NOTED: FDA blesses St. Jude heart valve; China Aoxing to sell narcotic for cancer pain;

> St. Jude Medical got the FDA's OK for a heart valve implant designed to protect against calcification. Report

> China Aoxing Pharmaceutical got its government's go-ahead to make and market Tilidine, a narcotic, to alleviate a shortage of meds for cancer pain. Report

> Beijing Med-Pharm has inked a deal to market and distribute Enablex, a Novartis drug for overactive bladder, in China. Report

> The leukemia drug dexamethasone causes extreme fatigue and sleeplessness in some children, according to a new study published in the online journal Cancer. Report

And Finally... Here's how to better predict liver toxicity: Use a teeny-tiny colony of living cells. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.